Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy
Hepatic TM6SF2 protects against MASLD-HCC and activates cytotoxic CD8<sup>+</sup> T cells via NF-κB-IL-6 axis. TM6SF2 is a promising strategy for sensitising MASLD-HCC to immunotherapy.
Authors
- Alvin H.K. Cheung (ORCID: https://orcid.org/0000-0002-3913-8117)
- Kwan Man (ORCID: https://orcid.org/0000-0001-5663-6866)
- Qian Song (ORCID: https://orcid.org/0000-0001-6545-8926)
- Mingxu Xie (ORCID: https://orcid.org/0000-0003-3394-4465)
- Harry Cheuk-Hay Lau (ORCID: https://orcid.org/0000-0003-3581-2909)
- Xiang Zhang (ORCID: https://orcid.org/0000-0002-3222-5824)
- Yali Liu (ORCID: https://orcid.org/0000-0002-8679-4133)
- Jun Qing Yu (ORCID: https://orcid.org/0000-0001-5008-2153)
- Weixin Liu (ORCID: https://orcid.org/0000-0002-1650-0371)
- Yating Zhang (ORCID: https://orcid.org/0000-0002-6927-8452)
- Yang Song (ORCID: https://orcid.org/0009-0006-2123-1600)
- Jun Wen (ORCID: https://orcid.org/0000-0002-6947-2087)
- Cong Liang (ORCID: https://orcid.org/0000-0002-5572-5354)
Institutions
- Sun Yat-sen University (CN)
- Chinese University of Hong Kong (HK)
- Chinese University of Hong Kong, Shenzhen (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Gut
- Published
- 2024-12-12
- DOI
- https://doi.org/10.1136/gutjnl-2024-333154
- Citations
- 11
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.25
Funders
- National Natural Science Foundation of China
- Chinese University of Hong Kong
- Innovation and Technology Fund
- Health and Medical Research Fund